Research Evidence
Pivotal Selectivity Study
A pivotal study published in the European Journal of Endocrinology established ipamorelin's selectivity, showing it released growth hormone in a dose-dependent manner without affecting ACTH, cortisol, prolactin, or thyroid-stimulating hormone levels, even at doses up to 100 mcg/kg.Bone Health Research
Research in animal models has demonstrated ipamorelin's potential for improving bone health. Studies in aged female rats showed that ipamorelin administration increased bone mineral content and improved bone formation markers.
Post-operative Recovery
A Phase II proof-of-concept study found that ipamorelin accelerated return of bowel function following abdominal surgery. However, Helsinn Healthcare's subsequent Phase II clinical trials for post-operative ileus were discontinued for lack of efficacy, and ipamorelin was not advanced further for this indication.